Status
Conditions
Treatments
About
Define the capability and reliability of the PulmoVista® 500 (PV500) to detect changes in global and regional ventilation and perfusion.
Full description
The results of this study will help defining the capability and reliability of PulmoVista® 500 (PV500) to detect changes in both global and regional ventilation and perfusion. As this is a non-invasive, observational trial, neither a positive nor a negative impact on the actual study participants is expected. The results will, however, improve the knowledge about the electrical impedance tomography (EIT) technology and thus aid the use of this technology for the benefit of future patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Contraindication to central venous injection of 5 % sodium chloride (NaCl) (e.g. elevated Na+ and/or Cl- concentration: Na+ should not exceed 150 mmol/l, Chloride should not exceed 115 mmol/l, known hypernatremia, known high serum osmolality)
Contraindications of PulmoVista 500:
Infection or colonization with multi-resistant pathogens that require isolation of the patient (e.g. MRSA)
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal